It is widely known that there is interindividual variation in the response to aspirin and clopidogrel, drugs that represent two major classes of antiplatelet therapies in use today.
Variation in response can be defined clinically, i.e., not all patients who are exposed to the drug are protected from platelet-mediated thrombotic events such as myocardial infarction (MI).
Response can also be defined pharmacodynamically in the laboratory employing ex vivo measures of platelet inhibition such as the VerifyNow® platform-a whole blood, point-of-care test. A rich history of epidemiologic and genetic data demonstrates an association between variability in laboratory responses and clinical outcomes among patients receiving antiplatelet therapy. To test the hypothesis that measures of ex vivo platelet function are truly risk factors and not merely risk markers, the ARCTIC study randomly assigned patients undergoing percutaneous coronary intervention (PCI) to a strategy of platelet function testing and subsequent adjustment of antiplatelet therapy vs. usual care. The primary results from ARCTIC failed to demonstrate a benefit from incorporating platelet function test results into management of antiplatelet therapies in this population. 1 In a secondary analysis published in this issue of The decision to perform a landmark analysis based on the time of hospital discharge was chosen in an effort to exclude periprocedural events. However, the collective data from prior and not merely risk markers, the ARCTIC study randomly assigned patients und de e ergo go g in in ng g g percutaneous coronary intervention (PCI) to a strategy of platelet function testing and subsequen ad dju ju ust st stm me ment nt nt o of f f an n nti ti tip pl platelet therapy vs. usual care. e T Th he primary resu su ults fr fr fro om om ARCTIC failed to d de dem mo monstrate a a be be ben ne efi fi it t fr from om om i inc nc ncor orpo po por ra rat ti in ng g pl la ate e elet fu u unc ct ti tio on on t t tes s st t r r re re esu u ult lts in i i t to o m m ma an anag agem em emen en nt of of of an nti ti tipl pl plat at a el elet et t t t the h hera ra api pi ies es i i in n th th t is i p p pop op opul ul ulat at atio ion n n. 1 1 In In In a s s sec ec e on on onda da ary ry ry a a an na naly ly ysi sis s s pu pu publ bl b i i ish he hed d in in in t t thi his s s i is issu u ue of of clinical trials of platelet P2Y12 receptor antagonists in PCI has shown that the bulk of events and benefit from therapy is concentrated within the first few days to weeks of therapy. [3] [4] [5] In ARCTIC, the vast majority (> 75%) of events occurred prior to hospital discharge. This "clustering" to the early phase following PCI is consistent with a platelet-mediated causal mechanism. Events that occur later or during the convalescence period following PCI are more heterogeneous in nature, and therefore less likely to be directly impacted by tailored antiplatelet therapy. The benefit of antiplatelet therapy may be greatest early during therapy in part because we and others have observed a waning effect of aspirin over time with the greatest inhibition of platelet function in the first 1-2 weeks of treatment initiation. 6, 7 Further, the strategy in response to detecting high, on-treatment platelet reactivity in ARCTIC included administration of a periprocedural glycoprotein IIb/IIIa inhibitor. After discharge, the most commonly selected strategies were increased clopidogrel or aspirin doses (prasugrel was rarely used)-neither has been shown to provide additional protection from ischemic events compared to standard doses. 8 Instead, it is conceivable that transition to either prasugrel or ticagrelor after discharge in those with high on-treatment platelet reactivity may have demonstrated a benefit. 3, 4 For each of the above reasons, it may have been particularly difficult to detect a signal of benefit from tailored antiplatelet therapy in the period following hospital discharge.
The findings from the landmark analysis do not resolve the unanswered question of whether a strategy of tailored antiplatelet therapy is beneficial for patients with acute coronary syndrome (ACS) who undergo PCI. Overall, participants in the ARCTIC trial were a low-tomoderate-risk group with only one-third presenting to the hospital with ACS. It may well be, based on the available information, that this latter group is most likely to benefit from a strategy of tailored antiplatelet therapy. Accordingly, one could conclude that the current analysis, o detecting high, on-treatment platelet reactivity in ARCTIC included administ tra ra ati ion o o o o of f f a a a pe pe peri riprocedural glycoprotein IIb/IIIa inhibitor. After discharge, the most commonly selected t tra ra ate te tegi gi gies es w w wer er re in in nc cr cre eased clopidogrel or aspirin d d dos ose es (prasugrel w w was r rar ar are el ely used)-neither has b be een n en shown to o pr pr ro ov vid id de e ad ad addi di diti ti tion o onal al p p pr ro rot te ec ct tion n n fr fr rom m is sche he em mi mic c e ev ven en nts s c com om mp pa are red d d t to to s sta ta tand nd ndar ar rd d do do dos se ses s. s 8 n nst st stea ea ad, d, d, i it t is is is c con once ce eiv iva ab ble le e t tha hat t t tr tran an ansi si sit ti tion on n t t to o o ei ei eith h her er e p p pra a asu su ugr gr grel el el o or r ti ti tica ca agr gr rel el e or or r r r a af afte ter r r di di disc scha ha har rg rge e e in n n t tho ho ose e e with high on n-t -t tre re reat at tme me ment nt n p p pla a ate te tele le let re re reac ac acti ti t vi i ity ty ty m m may ay ay h h hav av ave e e de de d mo mo mons ns nstr tr trat at ated ed ed a a a b b ben en enef ef efit it it. . . 3 3 3, 4 4 4 Fo Fo For r r ea ea each of the consistent with existing guidelines and prior studies, underscores a lack of evidence for routine platelet function testing and tailored therapy among low-to-moderate risk, non-ACS patients who undergo PCI. 9 10 In addition, these analyses do not exclude the possibility that a "response" to antiplatelet therapy is an actionable risk factor for platelet-mediated events. Ex vivo platelet function tests designed to gauge platelet aggregation in response to physiologic agonists are often selected as a road map to tailor antiplatelet therapy because of their ease of use and relative familiarity. This is a reasonable approach and, in principle, supports the National Institutes of Health's initiative for precision medicine as a means to deliver more affordable health care. 11 One must, however, an nd d d co co cond nd ndit it itio io ion n ns e emp mp mplo l yed poorly mimic in vivo pl pl plat ate elet and cellula la ar r bi iol ol olo og ogy. In addition, most ex vi ivo o o platforms s fo fo focu u us s p p prim im mar ar aril il ly y y on on p p pla la l te ele e et ag g gg gr rega a ati ion a an nd nd e e es ss sen entia al ally ly i i ign n nor ore e e s se secr cret et e io io ion, n, a adh dh dhes e esi io on, e eth th ther er rin in ing, g, g, a a and nd nd s sig ig gn na nali lin n ng. . Th They ey y a a als ls lso o o a ar are e in in nca ca cap p pabl bl ble e of of of p pr ro rovi vi vidi di ding ng ng e e ev v ven n n a a a g g glim m mme me mer r of of o a a a n n new w w w w wor orl l ld hat is rapidl ly y y em em emer er ergi gi g ng ng ng tha ha at t in in i cl cl clud ud u es es e t the he h p p pla la late te tele le let t t tr tr ran an ansc scri ri ript pt ptom om ome, e, e, p p pro o ote te teom om ome, e, e, m m met et etab ab abol ol olom om ome, post-are true "pharmacogenomic" biomarkers. This is to say that in the absence of clopidogrel, individuals who carry these variants have no differences in platelet function 16 or clinical outcomes 16, 17 A similar pattern may be emerging for PEAR1 variants in patients exposed to aspirin 18 , though this has not been a consistent finding 19 . In contrast, ex vivo platelet function test results are associated with comorbidities such as diabetes even in the absence of antiplatelet therapy 7 thus may more reflect overall risk than a specific response to a medication. Biomarkers with the same types of attributes as CYP2C19 and possibly PEAR1 may prove to be more useful in designing strategies to tailor the choice and/or duration of antiplatelet therapy.
In summary this secondary analysis by the ARCTIC investigators adds to an existing body of evidence 17, 20 that a strategy of tailored antiplatelet therapy around ex vivo platelet function is unlikely to benefit low-to-moderate risk PCI patients prescribed clopidogrel.
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